Guggenheim Maintains Buy on Verve Therapeutics, Lowers Price Target to $55
Portfolio Pulse from jenniferd'souza@benzinga.com
Guggenheim analyst Seamus Fernandez maintains a Buy rating on Verve Therapeutics (NASDAQ:VERV) but lowers the price target from $56 to $55.
August 15, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim maintains a Buy rating on Verve Therapeutics but lowers the price target from $56 to $55.
The news is directly related to Verve Therapeutics. While the maintained Buy rating is positive, the lowered price target might have a neutral impact on the stock as it indicates a slight decrease in the expected future value of the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100